$WW

DAVIS EUGENE I purchased $126K of WW

DAVIS EUGENE I purchased 10,000 shares of WW INTERNATIONAL, INC. (WW) at $12.63 ($0.13M total) on 2026-05-22.

Original reporting
SEC EDGAR · DAVIS EUGENE I
Published May 27, 2026, 8:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$WW
Neutral
low confidence
Mentioned
$WW
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WWNeutralLow
01

Why it matters

This disclosure may slightly improve sentiment among short-term traders, but it does not introduce new operating or financial information.

02

Market read

Treat as a low-signal sentiment datapoint unless corroborated by subsequent filings or fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the article provides no rationale for the buy, prior trading history, or whether the director’s holdings are material relative to total ownership.

Relevance 6/10Timing: Immediate (filed 2026-05-27) but likely more sentiment than catalyst.

Background

The article is an SEC Form 4 insider transaction: director Eugene I. Davis purchased WW shares in an open-market transaction.

Company-level read

Ticker impact

$WWNeutralLow confidence
Context

WW International disclosed a director open-market purchase of 10,000 shares for about $126.3K via SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely short-lived unless followed by additional buying or operational news.

Evidence & confidence

The filing is an ownership-change disclosure only (no earnings, guidance, deal, or regulatory update). The absence of a 10b5-1 plan and the director’s purchase may support sentiment, but size and lack of context reduce predictive power.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Insider purchases on Form 4 can reflect liquidity needs, diversification, or routine compensation-related behavior rather than a strong forward view.

Key entities

  • WW International, Inc.

    Subject of the Form 4 insider purchase disclosed on 2026-05-27.

  • DAVIS EUGENE I

    Director who reported an open-market purchase of 10,000 WW shares.

Related articles

$WWMed

WW International Q2 Earnings Call Highlights

WW International (NASDAQ:WW) reported Q2 average revenue per user up 10.2% YoY. Clinical subscription revenue rose 30.4% to $39.9M, while behavioral fell 22.7% to $121.5M. Gross margin was 70.3% (adjusted 73.6%). WW ended with $101.5M cash, repaid debt, and reaffirmed 2026 revenue $620M-$635M and adjusted EBITDA $105M-$115M.

$WWMed

WeightWatchers’s (NASDAQ:WW) Q2 CY2026: Beats On Revenue

WeightWatchers (NASDAQ:WW) reported Q2 CY2026 revenue of $162.3 million, down 14.2% year on year, but 2% above Wall Street estimates, according to the company. Full-year revenue guidance is $627.5 million at the midpoint, 0.7% below analysts’ estimates. GAAP profit was $1.41 per share above consensus; shares fell 1.3% to $15.23 after the report.

$WWMed

WW INTERNATIONAL, INC. (WW): Results of Operations and Financial Condition

WW INTERNATIONAL, INC. (WW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d15116dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Weight Watchers Announces Second Quarter 2026 Results Total End of Period Subscribers of 2.5 million; End of Period Clinical Subscribers of 197 thousand, up 55.7% year-over-year Core+ End of Period Subscribers of 541 thousan

$WWMedAI 8/10

Why WeightWatchers (WW) Stock Is Trading Up Today

WeightWatchers (NASDAQ: WW) shares rose 6.3% in the afternoon after the company said its Weight Watchers Med+ program is now available through Eli Lilly’s digital platform, LillyDirect. The program pairs GLP-1 prescription obesity drugs with behavioral, nutritional, and lifestyle support. The stock is down 45.5% year to date, at $17.13.